{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:14:48Z","timestamp":1794773688173,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The progressive fibrosing (PF) phenotype of interstitial lung disease (ILD) is characterised by worsening respiratory symptoms, lung function, and extent of fibrosis on high-resolution computed tomography. We aimed to investigate the prevalence and clinical outcomes of PF-ILD in a real-world cohort and assess the prognostic significance of the PF-ILD diagnostic criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical data of patients with fibrosing ILD other than idiopathic pulmonary fibrosis (IPF) consecutively diagnosed at a single centre were retrospectively reviewed. A PF phenotype was defined based on the criteria used in the INBUILD trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up duration was 62.7\u00a0months. Of the total of 396 patients, the mean age was 58.1\u00a0years, 39.9% were men, and rheumatoid arthritis-ILD was the most common (42.4%). A PF phenotype was identified in 135 patients (34.1%). The PF-ILD group showed lower forced vital capacity and total lung capacity (TLC) than the non-PF-ILD group. The PF-ILD group also showed poorer survival (median survival, 91.2\u00a0months vs. not reached; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) than the non-PF-ILD group. In multivariable Cox analysis adjusted for age, DL<jats:sub>CO<\/jats:sub>, HRCT pattern, and specific diagnosis, PF phenotype was independent prognostic factor (hazard ratio, 3.053; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in patients with fibrosing ILD. Each criterion of PF-ILD showed similar survival outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results showed that approximately 34% of patients with non-IPF fibrosing ILD showed a progressive phenotype and a poor outcome similar to that of IPF, regardless of the diagnostic criteria used.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-021-01879-6","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T16:02:27Z","timestamp":1635696147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Progressive fibrosing interstitial lung disease: prevalence and clinical outcome"],"prefix":"10.1186","volume":"22","author":[{"given":"Byoung Soo","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooae","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Sang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-3522","authenticated-orcid":false,"given":"Jin Woo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"1879_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35:2015\u201324.","journal-title":"Curr Med Res Opin"},{"key":"1879_CR3","doi-asserted-by":"publisher","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","volume":"51","author":"AU Wells","year":"2018","unstructured":"Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal Victor J. What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692.","journal-title":"Eur Respir J"},{"key":"1879_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"P-A Juge","year":"2018","unstructured":"Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209\u201319.","journal-title":"N Engl J Med"},{"key":"1879_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","volume":"5","author":"B Ley","year":"2017","unstructured":"Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5:639\u201347.","journal-title":"Lancet Respir Med"},{"key":"1879_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1164\/rccm.201902-0360OC","volume":"200","author":"B Ley","year":"2019","unstructured":"Ley B, Torgerson DG, Oldham JM, Adegunsoye A, Liu S, Li J, Elicker BM, Henry TS, Golden JA, Jones KD, et al. Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2019;200:1154\u201363.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00085-2020.","journal-title":"Eur Respir J"},{"key":"1879_CR8","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"1879_CR9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"1879_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020","author":"M Nasser","year":"2020","unstructured":"Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS\u00ae study). Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.02718-2020.","journal-title":"Eur Respir J"},{"key":"1879_CR11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.200611-1685OC","volume":"177","author":"WD Travis","year":"2008","unstructured":"Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177:1338\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR12","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","volume":"202","author":"G Raghu","year":"2020","unstructured":"Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, et al. Diagnosis of hypersensitivity pneumonitis in adults an official ATS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e36\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1879_CR14","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"1879_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9\u201316.","journal-title":"Ann Rheum Dis"},{"key":"1879_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N MacIntyre","year":"2005","unstructured":"MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720\u201335.","journal-title":"Eur Respir J"},{"key":"1879_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319\u201338.","journal-title":"Eur Respir J"},{"key":"1879_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1183\/09031936.05.00035005","volume":"26","author":"J Wanger","year":"2005","unstructured":"Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511\u201322.","journal-title":"Eur Respir J"},{"key":"1879_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;37:67\u2013119.","journal-title":"Eur Heart J"},{"key":"1879_CR21","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.","journal-title":"Eur Respir Rev"},{"key":"1879_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","volume":"17","author":"J Behr","year":"2017","unstructured":"Behr J, Neuser P, Prasse A, Kreuter M, Rabe K, Schade-Brittinger C, Wagner J, G\u00fcnther A. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017;17:122.","journal-title":"BMC Pulm Med"},{"key":"1879_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8:925\u201334.","journal-title":"Lancet Respir Med"},{"key":"1879_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s10067-018-4382-x","volume":"38","author":"Q Fu","year":"2019","unstructured":"Fu Q, Wang L, Li L, Li Y, Liu R, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol. 2019;38:1109\u201316.","journal-title":"Clin Rheumatol"},{"key":"1879_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/thoraxjnl-2017-210035","volume":"73","author":"A Gimenez","year":"2018","unstructured":"Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018;73:391\u20132.","journal-title":"Thorax"},{"key":"1879_CR26","doi-asserted-by":"publisher","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","volume":"54","author":"L Wollin","year":"2019","unstructured":"Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54:1900161.","journal-title":"Eur Respir J"},{"key":"1879_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1164\/rccm.200403-331OC","volume":"171","author":"Y Jegal","year":"2005","unstructured":"Jegal Y, Kim DS, Shim TS, Lim C-M, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639\u201344.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1164\/rccm.200210-1245OC","volume":"168","author":"PI Latsi","year":"2003","unstructured":"Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic Idiopathic Interstitial Pneumonia. Am J Respir Crit Care Med. 2003;168:531\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1879_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","volume":"42","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42:750\u20137.","journal-title":"Eur Respir J"},{"key":"1879_CR30","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1513\/AnnalsATS.201801-067OC","volume":"15","author":"SA Guler","year":"2018","unstructured":"Guler SA, Ellison K, Algamdi M, Collard HR, Ryerson CJ. Heterogeneity in unclassifiable interstitial lung disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2018;15:854\u201363.","journal-title":"Ann Am Thorac Soc"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01879-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T16:02:29Z","timestamp":1635696149000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01879-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01879-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Asan Medical Centre (IRB 2020-0705).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}